Deterministic design audit completed. Zero-violation coordinates locked.
Full chain elongation completed. Physical raw peptide cleaved and recovered.
Transitioned to specialized heated preparative HPLC to polish the 4 mg physical sample.
CD shape test and SPR binding kinetics scheduled at Helix.
The V37 Project Mission: take math, physics, and AI and write the code that can cure Cancer.
Interactive Target Action
Trigger the V37 therapeutic peptide to release the trapped p53 protein.
The human body already possesses a natural and highly effective tumor suppressor called the p53 protein. In half of all human cancers, the disease survives by overproducing an antagonist protein called MDM2, which physically binds to p53 and neutralizes it. This effectively holds the natural killer hostage, preventing the body from destroying the tumor. The body has its own cure, but cancer has it padlocked.
Traditional drug discovery takes years and millions of dollars testing random chemicals, hoping one might be the key that fits the lock. We bypassed this slow, legacy model and used high-dimensional computational physics, math, and AI to design a custom molecular key called V37. In effect, we coded a key from scratch to target MDM2, pry it off p53, and reactivate the body's natural defense systems.
Because our molecular key is designed to bind to its target with extreme strength, it is highly dense and water-repelling. This caused the molecule to behave like an industrial adhesive inside standard automated manufacturing systems. It literally stuck to the inside of standard commercial purification machines. Standard automated factories simply could not process it.
We solved the physical bottleneck. We designed a custom purification protocol using high heat (60 degrees Celsius) and specialized Isopropanol solvent washes to pry the molecule out of the machines. Through these custom engineering interventions, we successfully recovered four milligrams of the physical molecule. High-resolution mass spectrometers analyzed the resulting sample and confirmed the exact molecular weight of our key down to the decimal point: 1313.677. The math is now tangible matter.
The V37 static ribbon demonstrates a strict 3.6 residues per turn periodicity. This geometry perfectly aligns what we call the 'Golden Triad' of hydrophobic residues (Phenylalanine, Tryptophan, and Leucine) onto a single binding face, ensuring high-affinity contact with the MDM2 cancer target.
For clinical partners, investigators, and scientific supporters.
To ensure we did not design a digital illusion, we processed our SC-V37.0 structural files through the official wwPDB validation server. The server validated 100 percent sequence-to-coordinate correspondence with zero geometric violations, certifying the output as a Valid mmCIF.
Entry ID
D_9100127558
Status
Valid mmCIF
DiffDock is an impartial molecular docking AI developed by MIT and NVIDIA. We conducted a strict blind test where the algorithm received zero hints about where the binding pocket was located. In 20 separate runs, the AI independently discovered the exact same solution: it located the specific hydrophobic cleft of MDM2 and anchored the V37 peptide into the correct functional pose 20 out of 20 times.
Convergence
20 / 20 (100%)
Calculated Stability
-50.79 kcal/mol
Resonance Overlap
0.4674 (O-Score)
Developed by Duke University, MolProbity acts as a stereochemical diagnostic. V37 achieved a MolProbity Score of 2.06, placing it in the 72nd percentile for structural quality. It demonstrated flawless backbone geometry with exactly zero bad bonds, zero bad angles, and zero atomic clashes.
Favored Ramachandran
100.0% (18/18)
Bad Bonds
0 / 119 (0.0%)
Bad Angles
0 / 157 (0.0%)
Clash Score
0.00 (Perfect)